Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

NCT07333066 is registered in ClinicalTrials.gov with Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD as lead sponsor.

NCT NCT07333066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07333066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.
Lead sponsor
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Phase
Phase 3
Overall status
Recruiting
Start date
June 5, 2026
Completion date
March 31, 2030
Enrollment
320 (estimated)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic hormone-sensitive prostate cancer